TAPIT-1: Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1
Phase of Trial: Phase I
Latest Information Update: 24 May 2017
At a glance
- Drugs Treprostinil (Primary)
- Indications Chronic obstructive pulmonary disease; Pulmonary hypertension
- Focus Adverse reactions
- Acronyms TAPIT-1
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 18 Jul 2016 Status changed from recruiting to completed.
- 31 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016.